FDA, CISA advise on genomic device software vulnerabilities

While Illumina has yet to receive any reports indicating this vulnerability has been exploited, according to a letter to healthcare providers from the U.S. Food and Drug Administration, bad actors could take control of the devices, alter the software and patient test results or compromise a provider's network and exfiltrate protected data.

WHY IT MATTERS

The FDA released a statement Thursday for healthcare providers and laboratory personnel about the required actions that need to be taken to mitigate cybersecurity risks …